Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells

Zhen Li,1,6 Changqing Yu,1,a Yu Han,1 Hongmei Ren,1 Weibin Shi,1 Chunjiang Fu,1 Duofen He,1 Lan Huang,2 Chengming Yang,1 Xukai Wang,1 Lin Zhou,1 Laureano D. Asico,3 Chunyu Zeng,1 and Pedro A. Jose3,4

1Department of Cardiology, Daping Hospital, and 2Xinqiao Hospital, The Third Military Medical University, Chongqing, People’s Republic of China; and Departments of 3Pediatrics, 4Physiology and Biophysics, Georgetown University Medical Center, Washington, District of Columbia

Submitted 16 November 2007; accepted in final form 14 April 2008

Li Z, Yu C, Han Y, Ren H, Shi W, Fu C, He D, Huang L, Yang C, Wang X, Zhou L, Asico LD, Zeng C, Jose PA. Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 294: H2761–H2768, 2008. First published April 25, 2008; doi:10.1152/ajpheart.01344.2007.—The sympathetic nervous system plays an important role in the regulation of blood pressure. There is increasing evidence for positive and negative interactions between dopamine and adrenergic receptors; the activation of the α1-adrenergic receptor induces vasoconstriction, whereas the activation of dopamine receptor induces vasorelaxation. We hypothesize that the D1-like receptor and/or D3 receptor also inhibit α1-adrenergic receptor-mediated proliferation in vascular smooth muscle cells (VSMCs). In this study, VSMC proliferation was determined by measuring [3H]thymidine incorporation, cell number, and uptake of 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT). Norepinephrine increased VSMC number and MTT uptake, as well as [3H]thymidine incorporation via the α1-adrenergic receptor in aortic VSMCs from Sprague-Dawley rats. The proliferative effects of norepinephrine were attenuated by the activation of D1-like receptors or D3 receptors, although a D1-like receptor agonist, fenoldopam, and a D3 receptor agonist, PD-128907, by themselves, at low concentrations, had no effect on VSMC proliferation. Simultaneous stimulation of both D1-like and D3 receptors had an additive inhibitory effect. The inhibitory effect of D3 receptor was via protein kinase C-ζ, whereas the D1-like receptor effect was via protein kinase C-ζ. The interaction between α1-adrenergic and dopamine receptors, especially D1-like and D3 receptors in VSMCs, could be involved in the pathogenesis of hypertension.

α1-adrenergic receptor; hypertension

CARDIOVASCULAR DISEASE REMAINS the major cause of death in the world, and hypertension accounts for the major cause of these deaths in the United States and Western Europe (46). Hypertension is known to be associated with an increase in sympathetic activity (8, 42). The sympathetic neurotransmitters, norepinephrine and epinephrine, play important roles in the regulation of physiological and pathological processes in the cardiovascular system, via binding to adrenoceptors (21). Vascular smooth muscle cell (VSMC) proliferation is central to the development of vascular diseases, such as restenosis and atherosclerosis. In addition to the fact that prolonged elevation of plasma catecholamines is a risk factor for vascular diseases, recent reports have shown that catecholamines directly induce hypertrophy of the arterial wall by stimulation of α1-adrenoceptors (7, 10). Catecholamines in cell and organ culture induce dose-dependent proliferation of VSMCs, and the trophic effect is dependent on the production of reactive oxygen species (5). Furthermore, the potency of these effects is strongly augmented in hypertensive states (47, 55, 60).

Although dopamine is a precursor of norepinephrine and epinephrine, by itself it also exerts widespread effects both in neuronal and nonneuronal tissues (18, 57). Dopamine receptors, classically, have been divided into D1- and D2-like subtypes based on their interaction with the effector enzyme, adenyl cyclase. The D1-like receptors, which stimulate adenyl cyclases, are composed of the receptor subtypes D1 and D5 receptors, whereas the D2-like receptors, which inhibit adenyl cyclase, are composed of the subtypes D2, D3, and D4 receptors (18, 57). Both D1-like and D3 receptors have been found in conduit and resistance arteries, including the aorta, mesenteric artery, and renal artery (2, 34, 36, 53, 54, 60).

Dopamine, at low concentrations, via D1-like receptors, relaxes blood vessels and decreases blood pressure (18, 57). We have reported that in the rat mesenteric artery, D3 receptor agonist has no effect on vascular contractility. However, when the mesenteric rings are preconstricted with potassium chloride or norepinephrine, stimulation of D1-like receptors or the D3 receptor causes vasorelaxation (60). When compared with vessels preconstricted with norepinephrine, the D1-like receptor- and D3 receptor-mediated vasorelaxation is greater in vessels preconstricted with norepinephrine than in vessels preconstricted with potassium chloride, indicating that norepinephrine could impair the vasodilatory effect of dopamine (60). Dopamine also has antiproliferative effects, via D1-like receptors in neuronal and VSMCs (41, 53, 54). Dopamine receptors have been reported to inhibit or stimulate cell proliferation that is subtype dependent (3, 27). We hypothesize that in addition to opposing the vasoconstrictor effect of norepinephrine in the artery, activation of D1-like and D3 receptors reduces the proliferative effects mediated by norepinephrine, via α1-adrenergic receptor. To test this hypothesis, we used VSMCs from the aorta of Sprague-Dawley (SD) rats. We found that the activation of D1-like or D3 receptor reduces the proliferative effects mediated by norepinephrine, via the α1-adrenergic receptor; costimulation of D1-like and D3 recep-

* Z. Li and C. Yu are co-first authors.

Address for reprint requests and other correspondence: C. Zeng, Dept. of Cardiology; Daping Hospital, The Third Military Medical Univ., Chongqing 400042, P. R. China (e-mail: chunyu_zeng01@163.com).

http://www.ajpheart.org 0363-6135/08 $8.00 Copyright © 2008 the American Physiological Society H2761

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Downloaded from http://ajpheart.physiology.org/ by 10.220.33.5 on July 6, 2017
tors has an additive antiproliferative effect in VSMCs from SD rats. Moreover, we found that protein kinase A (PKA) is involved in the D₁ receptor-mediated antiproliferative effect, whereas protein kinase C (PKC) is involved in the D₁-like receptor-mediated antiproliferative effect.

**Methods**

Aortic smooth muscle cell isolation and culture. The tunica media were dissected from freshly harvested aortic strips from 200-g SD rats and plated in 100-mm petri dishes using standard explant techniques (26). Briefly, the aorta was incised longitudinally, and the endothelial cells were removed by vigorously scraping the surface of the lumen with a scalpel blade to expose the medial layer of the vessel. The vessel was then divided into 1-cm sections and placed lumen-side down in 60-mm petri dishes containing VSMC medium (Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 20\% FBS (HyClone) and 1\% penicillin/streptomycin/β-EGF/insulin/EGF (all from Sigma, St. Louis, MO)) and cultured at 37°C in a humidified 5\% CO₂/95\% room air atmosphere for 2 wk to allow for VSMC migration from the vessel onto the dish. Explant-derived cells were initially treated with 0.1\% trypsin, and 4 mM EDTA for 3 min at 37°C, and thereafter the passage was performed conventionally. Cells from passages 5–15 were used for all growth studies. The cells were characterized as smooth muscle cells by morphology (multilayer sheets, “hills and valleys”) and immunostaining with monoclonal antibody specific for smooth muscle α-actin. Cells were subcultured into 24-well plates in a medium containing 10\% serum for 24 h with an initial density of 5 × 10⁴ cells per well. The cells were then placed in the medium without serum for 24 h to render them quiescent. All experiments were approved by the Third Military Medical University Animal Use and Care Committee.

Evaluation of cell number. VSMCs were seeded in six-well plastic culture dishes at a density of 1 × 10⁴/well in DMEM containing 10\% FBS and cultured for 24 h. After the induction of quiescence, the medium was replaced with serum-free medium with the indicated drug concentrations (fenoldopam, 10⁻⁷ M; PD-128907, 10⁻⁷ M; and norepinephrine, 10⁻⁶ M) and incubated for another 24 h. The experiment was terminated by aspiration of the medium and washing with phosphate-buffered saline (PBS) followed by the addition of 1 ml of 2\% (wt/vol) trypsin to each dish. After the collection of the cells, viable cells, determined by the uptake of 0.4\% trypan blue after 5 min of mixing (Invitrogen Life Technologies), were counted using a hemocytometer (trypan blue uptake was observed in viable cells, determined by the uptake of 0.4\% trypan blue after 5 min of mixing (Invitrogen Life Technologies), were counted using a hemocytometer (trypan blue uptake was observed in <10\% of the cells). Counting was performed in triplicate (35, 49).

MTT assay. The number of viable cells in each well was also estimated by the uptake of the tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT). MTT, selectively taken up by mitochondria, is converted to a dark-blue product by living but not by dead cells. After the induction of quiescence in 96-well plastic culture dishes at the density of 1×10⁵ cells/well, the cells were incubated with the indicated drugs for 24 h. Subsequently, 20 µl of MTT (2.5 g/l) were added to each well, and the incubation continued for an additional 4 h at 37°C. Thereafter, 150 µl DMSO were added to each well, and an absorbance at 490 nm was read on a Microplate reader (model 680, Bio-Rad) (25, 26).

[^3H]thymidine incorporation. Cell proliferation was determined by measuring the incorporation of [^3H]thymidine (Atomic Energy Research Establishment of China, Beijing City, China) into DNA of cells cultured in 96-well plates. After the induction of quiescence, the cells were stimulated with norepinephrine (Huofen, Shanghai City, China), vehicle (distilled H₂O) in the presence or absence of the indicated drugs; PD-128907 (Sigma), a D₁ receptor agonist; and fenoldopam (Sigma), a D₁-like receptor agonist, for 24 h. All of antagonists or inhibitors were added into the medium 30 min before the corresponding agonists or activators. [^3H]thymidine (1 µCi/ml) was then added to the growth medium of each well 6 h before the measurements. At the end of incubation, the medium was removed and the cells were treated with 0.25 ml of 0.05% trypsin-0.53 mM EDTA (Gibco, Grand Island, NY) for 5 min and diluted to 10 ml with a balanced electrolyte solution (17, 26). The cells were then treated with 10\% trichloroacetic acid to precipitate acid-insoluble materials from which the DNA was extracted with 0.1 M NaOH. The DNA was collected on a Whatman GF/B filter and washed twice with 5 ml ice-cold PBS. The filter was then cut and shaken in 3.5 ml scintillation fluid for 24 h before counting in a liquid scintillation counter (Beckman LS6500, Beckman). Data are presented as [^3H]thymidine uptake per microgram of protein.

To determine the specificity of the D₁-like and D₃ receptor agonists, D₁-like receptor and D₃ receptor antagonists, SCH-23390 (Sigma) and U-99194A (Research Biochemicals International, Natick, MA), respectively, were used to block the effect of fenoldopam or PD-128907. There are no ligands, agonists, or antagonists that can distinguish between D₁ and D₃ receptors; therefore, the receptors involved in this experiment are D₁-like receptors (D₁ and D₃), which are expressed in the VSMCs of rats. To determine whether the proliferative effect of norepinephrine is exerted at the α₁-adrenergic receptor, the α₁-adrenergic receptor antagonist prazosin (Sigma) was used.

Determination of the second messenger(s) involved in the antiproliferative effects of D₁-like and D₃ receptors. To determine the second messenger(s) involved in the effect of D₁-like and D₃ receptors, cell permeable, myristoylated peptide inhibitors of PKC (peptide 19–31) (20), PKA (14–22 amide) (6) (Calbiochem, Darmstadt, Germany), and myristoylated PKC-ζ pseudosubstrate inhibitor (Calbiochem, Darmstadt, Germany) (37, 51) were used. To determine the specificity of PKC and PKA inhibitors, PKC activator, phorbol 12-myristate 13-acetate (PMA, Sigma), and PKA activator, 8-(4-chlorophenylthio) adenosine-3’,5’-cyclic monophosphorothioate, Sp-isomer sodium salt (Sp-cAMP[S], Sigma) were used.

Statistical analysis. The data are expressed as means ± SE. The comparison within groups was made by repeated-measures ANOVA (or paired t-test when only 2 groups were compared), and the comparison among groups (or t-test when only 2 groups were compared) was made by factorial ANOVA and Duncan’s test. A value of P < 0.05 was considered significant.
RESULTS

Norepinephrine, via the $\alpha_1$-adrenergic receptor, increases proliferation of VSMCs from rat aorta of SD rats. Treatment of VSMCs with varying concentrations of norepinephrine ($10^{-6}$–$10^{-3}$ M) for 24 h resulted in a concentration-dependent increase in $[^{3}H]$thymidine incorporation in aortic VSMCs from SD rats (data not shown). The increase in $[^{3}H]$thymidine incorporation, induced by norepinephrine, was blocked by the $\alpha_1$-adrenergic receptor antagonist, prazosin (Fig. 1), indicating that the norepinephrine-mediated proliferation was via the $\alpha_1$-adrenergic receptor.

The norepinephrine-mediated proliferation of VSMCs from rat aorta of SD rats is attenuated by a D1-like receptor agonist. To investigate whether there is an interaction between $\alpha_1$-adrenergic and D1-like receptors, VSMCs were incubated with norepinephrine and the D1-like receptor agonist, fenoldopam, for 24 h. Fenoldopam, by itself, had no effect on $[^{3}H]$thymidine incorporation (data not shown), but dose-dependently ($10^{-12}$–$10^{-5}$ M) reduced the stimulatory effect of norepinephrine (Fig. 2A). The effect of fenoldopam was via the D1-like receptor, because the inhibitory effect of fenoldopam on norepinephrine-mediated proliferation was blocked by the D1-like receptor antagonist, SCH-23390 (Fig. 2B).

The PKC inhibitor peptide 19–31 (10$^{-5}$ M) was used in this experiment. It resulted that myr-RGRARRWRK, by itself, had no effect on VSMC proliferation but blocked the inhibitory effect of fenoldopam on norepinephrine-mediated proliferation (Fig. 2D), indicating that PKC-$\zeta$ was involved in the inhibitory action of fenoldopam.

To further investigate which isoform of PKC was involved in the mechanism, myristoylated PKC-$\zeta$ pseudosubstrate inhibitor (10$^{-5}$ M) was used in this experiment. It resulted that myr-RGRARRWRK, by itself, had no effect on VSMC proliferation but blocked the inhibitory effect of fenoldopam on norepinephrine-mediated proliferation (Fig. 2D), indicating that PKC-$\zeta$ was involved in the inhibitory action of fenoldopam.
The specificity of PKC inhibitor, peptide 19–31, on norepinephrine-mediated proliferation was also determined. The PKC activator, PMA, by itself, had no effect on VSMC proliferation but reduced the norepinephrine-mediated proliferation in aortic VSMCs from SD rats, which was blocked by the PKC inhibitor peptide 19–31 (Fig. 2E).

The norepinephrine-mediated proliferation of VSMCs from rat aorta of SD rats is reduced by a D3 receptor agonist. To determine whether there is any effect of D3 receptors on cell proliferation, the VSMCs from SD rats were treated with varying concentrations (10^{-8}, 10^{-5} M) of the D3 receptor agonist, PD-128907 (58). We found that at low concentrations (10^{-8} and 10^{-7} M), PD-128907 had no effect on cell proliferation but at high concentrations (10^{-6} and 10^{-5} M), PD-128907 stimulated VSMC proliferation (data not shown). The stimulatory effect of PD-128907 on VSMC proliferation was blocked by the α1-adrenergic receptor blocker prazosin, but not by D3 receptor antagonist U-99194A, indicating that the stimulatory effect of the high concentrations of PD-128907 is via the α1-adrenergic receptor rather than the D3 receptor (concentration 10^{-4}, 10^{-3}, and 10^{-2} M).

To investigate whether there is an interaction between α1-adrenergic and D3 receptors, VSMCs were incubated for 24 h with norepinephrine (10^{-6} M) and low concentrations of the D3 receptor agonist PD-128907. PD-128907 (10^{-12}–10^{-7} M), by itself, had no effect but reduced the stimulatory effect of norepinephrine on [3H]thymidine incorporation in aortic VSMCs from SD rats (Fig. 3A). The effect of PD-128907 was via the D3 receptor, because the inhibitory effect of PD-128907 on norepinephrine-mediated proliferation was blocked by D3 receptor antagonist U-99194A (Fig. 3B).

The PKA inhibitor 14–22 (10^{-6} M), by itself, had no effect on VSMC proliferation. The PKA inhibitor also did not affect norepinephrine-mediated VSMC proliferation but blocked the inhibitory effect of PD-128907, indicating that PKA was engaged in the inhibitory action of PD-128907 (Fig. 3C). We also used a PKC inhibitor (19–31) and a calcium channel blocker (nicardipine) in this experiment. However, neither 19–31 nor nicardipine could block the effect of D3 receptor on VSMC proliferation (data not shown).

The specificity of PKA inhibitor 14–22 on norepinephrine-mediated proliferation was also determined in this experiment. PKA activator, Sp-cAMP[S], by itself had no effect on VSMC proliferation but reduced the norepinephrine-mediated proliferation in aortic VSMCs from SD rats, which was blocked by the PKA inhibitor 14–22 (Fig. 3D).

Fig. 3. Effect of D3 receptor on NE-mediated proliferation of aortic VSMCs from SD rats. A: effect of D3 receptor agonist PD-128907 (PD) on NE-mediated proliferation of aortic VSMCs from SD rats. VSMC proliferation was determined by [3H]thymidine incorporation after incubation with the indicated concentrations of NE (10^{-6} M) with or without the presence of PD (10^{-12}–10^{-7} M). B: effect of a D3 receptor agonist PD and D3 receptor antagonist U-99194A (U) on NE-mediated proliferation of aortic VSMCs from SD rats. The cells were incubated with the indicated reagents: PD (10^{-7} M) and U (10^{-7} M) for 24 h. VSMC proliferation was determined by [3H]thymidine incorporation. C: effect of PKA inhibitor, protein kinase A inhibitor 14–22 (PKAI), on the inhibitory effect of D3 receptor in aortic VSMCs from SD rats. The cells were incubated with the indicated reagents: NE (10^{-6} M), PD (10^{-7} M), and PKAI (10^{-8} M) for 24 h. VSMC proliferation was determined by [3H]thymidine incorporation. D: effect of PKA activator 8-(4-chlorophenylthio)adenosine-3',5'-cyclic monophosphorothioate, Sp-isomer sodium salt (Sp-cAMP[S]: PKAA) and PKAI on NE-mediated proliferation of aortic VSMCs from SD rats. The cells were incubated with the indicated reagents: NE (10^{-6} M), PKAI (10^{-6} M), and Sp-cAMP[S] (10^{-7} M) for 24 h. VSMC proliferation was determined by [3H]thymidine incorporation. All results are expressed as cpm/mg protein [n = 9 (A), n = 5 (B), n = 8 (C), and n = 4 (D) experiments]. *P < 0.05 vs. control; **P < 0.01 vs. control; #P < 0.05 vs. PE (ANOVA, Duncan’s test).
D_1-like and D_3 receptors have additive inhibitory effect on norepinephrine-mediated VSMC proliferation. In additional studies, we found that costimulation with D_1-like and D_3 receptor agonists, fenoldopam (10^{-7} M) and PD-128907 (10^{-7} M), reduced norepinephrine-mediated proliferation to a greater degree than those observed with fenoldopam or PD-128907, indicating an additive effect of D_1-like and D_3 receptors (Fig. 4A).

To substantiate the above-mentioned phenomena determined by [^{3}H]thymidine incorporation, we investigated VSMC proliferation further by counting the number of viable cells, determined by counting 0.4% trypan blue-positive cells and by the MTT method. In agreement with the [^{3}H]thymidine incorporation method, norepinephrine increased the number of VSMCs that was reduced in the presence of D_1-like and D_3 receptor agonists, fenoldopam (10^{-7} M) and PD-128907 (10^{-7} M), respectively. Moreover, costimulation with fenoldopam and PD-128907 reduced the norepinephrine-mediated increase in cell number to a greater extent than those observed with fenoldopam or PD-128907, indicating an additive effect of D_1-like and D_3 receptors (Figs. 4, B and C).

**DISCUSSION**

There are several novel observations in our study. We show that the proliferative effect of norepinephrine, via an α_1-adrenergic receptor, in VSMCs from the aorta of SD rats is reduced by the activation of D_1-like or D_3 receptors, although the D_1-like and D_3 receptors, by themselves, have no effect on VSMC proliferation. The D_1-like and D_3 receptors have an additive inhibitory effect on norepinephrine-mediated proliferation of VSMCs. The inhibitory effect of D_3 receptor is via PKA, whereas D_1-like receptor effect is via PKC.

The sympathetic neurotransmitters, norepinephrine and epinephrine, via α-adrenergic receptors, induce vasoconstriction and proliferation of VSMCs, whereas the opposite effects (vasodilation and inhibition of the proliferation of VSMCs) occur via β-adrenergic receptors (16, 60). Dopamine at low concentrations, via dopamine receptors, dilates the resistance and capacitance arteries (18, 23, 57); at high concentrations, dopamine stimulates other G protein-coupled receptors, including α,β-adrenergic receptors (18, 57) and serotonin receptors (14, 50).

There are increasing pieces of evidence for interactions among catecholamines and their receptors in neural and non-neural tissues. The D_2-like receptors, D_2, D_3, and D_4, are located pre- and postsynaptically/junctionally (2, 30, 45, 60). Presynaptic D_2 dopamine receptors in postganglionic sympathetic nerves innervating various organs, including human gastric and uterine arteries, can inhibit the release of catecholamine (28). In contrast, the blockade of the presynaptic α_2-adrenergic receptor enhances brain cortical dopamine output (15). An activation of human peripheral blood mononuclear cells triggers endogenous production of catecholamines, an effect that is blocked by an activation of D_1-like receptor. The counterregulatory actions of the α-adrenergic and dopamine receptors extend to the effects on vascular proliferation.

Our previous study showed that D_1 and D_3 receptors exist in the artery. Stimulation of D_1-like or D_3 receptor can increase both receptor protein expression in rat aorta A10 cells; the activation of D_1-like or D_3 receptor relaxes rat mesenteric arteries preconstricted by potassium chloride, and the simultaneous stimulation of D_1-like and D_3 receptors has an additive relaxant effect (60). The present results show that the D_1-like or D_3 receptor has an inhibitory effect on norepinephrine-induced VSMC proliferation, and costimulation of D_1-like and

---

Fig. 4: A: Effect of D_1-like and D_3 receptors on NE-mediated proliferation of aortic VSMCs from SD rats. A: VSMC proliferation was determined by [^{3}H]thymidine incorporation after incubation with the indicated concentrations of NE (10^{-6} M) with or without the presence of PD (10^{-7} M) and Fen (10^{-7} M). Results are expressed as cpm/mg protein (n = 8 experiments). B: VSMC proliferation was determined by cell number after incubation with the indicated concentrations of NE (10^{-6} M) with or without the presence of PD (10^{-7} M) and Fen (10^{-7} M). Results are expressed as cell number per well (n = 4 experiments). C: VSMC proliferation was determined by the 3-(4,5-dimethyl-thiazol-2-yl)-diphenyltetrazolium bromide (MTT) method after incubation with the indicated concentrations of NE (10^{-6} M) with or without the presence of PD (10^{-7} M) and Fen (10^{-7} M). Results are expressed as MTT optical density (OD) = 490 nm (n = 14 experiments). *P < 0.01 vs. control; #P < 0.05 vs. NE, &P < 0.05 vs. NE + Fen or NE + PD (ANOVA, Duncan’s test).
D3 receptors has an additive inhibitory effect, which further indicates the interaction between D1-like and D3 receptors in the artery.

α1-Adrenergic receptors, like dopamine receptors, are members of the class A of G protein-coupled receptors and mediate many of the physiological effects of catecholamines. The α1-adrenergic receptor plays a particularly important role in the regulation of blood pressure via the activation of smooth muscle replication and contraction. Consistent with our findings in this study, the activation of α1-receptors stimulates vascular smooth muscle growth (19). Human VSMCs express at least three subtypes of α1-receptors, namely, α1A-, α1B-, and α1D-receptors. It is generally accepted that the activation of all three subtypes of α1-receptors increases the hydrolysis of phosphatidylinositol 4,5-bisphosphate to form inositol 1,4,5-trisphosphate and diacylglycerol via Gα, leading to the activation of PKC and an increase in intracellular Ca2+ (29). Substantial evidence indicates that the activation of PKC or Ca2+ channel is involved in the α1-adrenergic receptor induction of mitogenesis in VSMCs (22). In this study, we show that the activation of D1-like or D3 receptors has an inhibitory effect on norepinephrine-induced proliferation in VSMCs. However, the mechanism(s) of the antiproliferative action of D1-like or D3 receptor is not clear. Our studies show that the inhibitory effect of D3 receptor is blocked by treatment with PKA inhibitor, whereas the D1-like receptor inhibitory effect is blocked by the inhibition of PKC activity, indicating that PKA and PKC are involved in these actions. High concentrations of D1-like or D3 receptor agonists can also compete with norepinephrine for adrenergic receptor occupancy to some degree. However, our studies used low concentrations of D1-like or D3 receptor agonists that can be blocked by their respective antagonists but not by an α1-adrenergic receptor antagonist. However, it is interesting to find that PKA and PKC are involved in the D1-like and D3 receptor-mediated antiproliferative effects.

PKC isoforms are classified into four groups, the conventional PKCs (α, βI, βII, and γ), the novel PKCs (δ, ε, η, and θ), the atypical PKCs (ζ and λ/λ), and PKD or PKC-μ. In this study, we could not determine which one is involved in the antiproliferative effects by D1-like receptor. The activities of novel and atypical PKCs are not affected by Ca2+, whereas conventional PKCs can bind Ca2+ (39, 44). In renal proximal tubule cells, the activation of D1-like receptor can stimulate (θ and ζ) or inhibit (δ) new PKCs or translocate specific PKC isoforms from cytosol to membrane (α, β, and ε) and membrane to cytosol (δ) (9, 32, 52, 56). There are reports that PKC-β1, PKC-δ, PKC-ε, PKC-ζ, and PKC-η have proliferative VSMC effects (1, 56). In our studies, a Ca2+ channel blocker has no effect on the α1-adrenoceptor-mediated proliferation effect; therefore, it is possible that atypical and novel PKCs, and not conventional PKCs, are involved in this action. In this experiment, we found that the inhibition of PKC-ζ blocks the inhibitory effect of fenoldopam on norepinephrine-mediated proliferation, indicating that PKC-ζ is involved in the inhibitory action of fenoldopam.

Our present study found that the D3 receptor mediated the inhibition of VSMC proliferation is via PKA. Whereas the D3 receptor is usually linked to adenyl cyclase inhibition, the D3 receptor can also be linked to its stimulation (33). The D1-like receptor-mediated inhibitory effect on VSMC proliferation is blocked by the inhibition of PKC activity, indicating that PKC is involved in this action. This is in contrast to the study of Yasunari et al. (53), who found that the antiproliferative effect of D1-like receptors is mediated, in part, by the inhibition of PKC activity. The reason for this difference between these two studies is not known; however, there are differences between our study and those reported by Yasunari et al. (53). First, we used VSMCs from the aorta of SD rats, whereas Yasunari et al. used VSMCs from the renal artery of Wistar rats. The differences may be vessel specific (conduit and resistance vessels or differences among resistance vessels, e.g., mesenteric vs. renal VSMCs). It should be noted, however, that it would be unlikely for D1 receptors to inhibit PKC activity because the D1 receptor, by itself, or via an interaction with the D2 receptor (24, 40) has been consistently reported to stimulate and not inhibit phospholipase C, the enzyme proximal to PKC activation, initially reported by Felder et al. in renal tubules (4, 11, 12) and subsequently confirmed in other tissues, including neural tissue (31, 48) and VSMCs (43). D1-like receptors have also been reported to stimulate (e.g., PKC-ε) (10, 14, 33) or inhibit (e.g., PKC-δ) specific PKC isoforms (52, 59) that are cell specific. Second, the proliferative factors are different: we used norepinephrine, whereas Yasunari et al. used PDGF.

In summary, we have demonstrated that the proliferative effect of norepinephrine, via the α1-receptor, on VSMCs from rat aorta is reduced by the activation of D1-like or D3 receptors. A simultaneous stimulation of D1-like and D3 receptors has an additive inhibitory effect on norepinephrine-mediated proliferation of VSMCs. The inhibitory effect of D3 receptor is via PKA, whereas the D1-like receptor effect is via PKC-ζ.

Perspectives. VSMC proliferation plays an important role in the pathogenesis of hypertension. Norepinephrine, via the α1-receptor, increases VSMC proliferation, whereas dopamine, via the D1-like and D3 receptors, reduces norepinephrine-mediated proliferative effects. The development of drugs, which selectively activate dopamine receptors, might be helpful to prevent vessel wall hypertrophy and hyperplasia, reduce peripheral arterial resistance, and normalize blood pressure.

GRANTS

These studies were supported in part by National Institutes of Health Grants HL-23081, DK-39308, HL-68686, HL-62211, and HL-074940, National Natural Science Foundation of China Grants 30470728 and 30672199, and the National Basic Research Program of China (973 Program, 2008CB517308).

REFERENCES


